Investigation of relationships among upper abdominal symptoms, findings of esophagogastroduodenoscopy (EGD) and quality of life (QOL) and comparing study of therapeutic effects of various gastrointestinal drugs on upper abdominal symptoms of patients with functional dyspepsia (FD) or non-errosive reflux disease (NERD) by using questionnaires to evaluate upper abdominal symptoms (GOS) and QOL (SF-8).

Investigation of relationships among upper abdominal symptoms, findings of esophagogastroduodenoscopy (EGD) and quality of life (QOL) and comparing study of therapeutic effects of various gastrointestinal drugs on upper abdominal symptoms of patients with functional dyspepsia (FD) or non-errosive reflux disease (NERD) by using questionnaires to evaluate upper abdominal symptoms (GOS) and QOL (SF-8). - Evaluation of therapeutic effects of various gastrointestinal drugs on upper abdominal symptoms and QOL of patients with FD or NERD by GOS and SF-8 questionnaires.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002432

Enrollment

600

Registered

2009-09-15

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia (FD), Non-erosive reflux disease (NERD)

Interventions

Subjects with more than 4 points of GOS score at least one item and no organic disease certified by EGD are medicated with any of the following drugs 1) - 4) for 2weeks, and then answer the questionna

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who meet the following requirements 1) - 3) with their consents to participate in the present study are selected from the examinees undergoing a work-up EGD as a part of a mass-screening program for gastric cancer, who answer questionnaires of GOS and SF-8 prior to EGD; 1)GOS score show more than 4 points at least one item. 2)No organic disease is certified by EGD. 3)Patients desire to medicate their upper abdominal symptoms.

Exclusion criteria

Exclusion criteria: 1)Examinees have organic diseases detected by EGD including peptic ulcer, malignant neoplasm, reflux esophagitis more than grade A of LA classification, etc. 2)Examinees undergoing forceps biopsy during EGD 3)examinees with a past history of Helicobacter pylori eradication therapy

Design outcomes

Primary

Measure	Time frame
Changes in scores of GOS (Global Overrall Sverity) and SF-8 (iHope International) questionnaires prior to EGD, at 1 week and 2 weeks after medications	—

Secondary

Measure	Time frame
1)Findings of EGD 2)Urinary anti-Helicobacter pylori antibody	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026